Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Guided Posters

Pituitary Basic

ea0056gp194 | Pituitary Basic | ECE2018

Olfactory marker protein regulates prolactin secretion and production by modulating Ca2+ and TRH signaling in lactotrophs

Ku Cheol Ryong , Kang Chan Woo , Kim Daham , Hong Jae Won , Kim Sun Ho , Lee Eun Jig

Olfactory marker protein (OMP) is a marker of olfactory receptor-mediated chemoreception, even outside the olfactory system. Here, we report that OMP expression in the pituitary gland plays a role in basal and thyrotropin-releasing hormone (TRH)-induced prolactin (PRL) production and secretion. We found that OMP was expressed in human and rodent pituitary glands, especially in PRL-secreting lactotrophs. OMP knockdown in GH4 rat pituitary cells increased PRL production and secr...

ea0056gp195 | Pituitary Basic | ECE2018

Filamin A (FLNA) phosphorylation inhibits SSTR2 signal transduction in GH-secreting pituitary tumor cells

Peverelli Erika , Catalano Rosa , Giardino Elena , Mangili Federica , Treppiedi Donatella , Arosio Maura , Spada Anna , Mantovani Giovanna

Despite the increasing evidence on the relevance of the actin binding protein filamin A (FLNA) in determining an efficient intracellular response to somatostatin analogs (SSA) in pituitary tumors, there is a gap in the knowledge on the mechanisms regulating FLNA itself. FLNA is phosphorylated by PKA on Ser2152 located in a FLNA region crucial for SST2 or partner proteins binding. Although cAMP/PKA pathway plays a crucial role in GH-secreting tumors pathogenesis, the...

ea0056gp196 | Pituitary Basic | ECE2018

E-cadherin expression is associated with the response to somatostatin analogues in patients with acromegaly

Cano David A , Venegas-Moreno Eva , Gros-Herguido Noelia , Dios Elena , Flores-Martinez Alvaro , Gonzalez Natividad , Madrazo-Atutxa Ainara , Cardenas Eugenio , Kaen Ariel , Castano Justo P , Luque Raul M , Soto-Moreno Alfonso

Aim: To assess whether E-cadherin expression levels in somatotropinomas were associated with the response to somatostatin analogues (SSAs) therapy in patients with acromegaly.Methods: In this retrospective study, 56 acromegaly patients that underwent transsphenoidal surgery were evaluated. All patients were treated preoperatively with SSAs (octreotide or lanreotide) for at least 6 months. Responsiveness to SSAs was evaluated by percent IGF-1 reduction af...

ea0056gp197 | Pituitary Basic | ECE2018

Efficacy of pharmacological USP8 inhibition in human Cushing’s disease tumours in vitro

Theodoropoulou Marily , Perez-Rivas Luis , Albani Adriana , Stalla Gunter , Buchfelder Michael , Flitsch Joerg , Honegger Juergen , Rachinger Walter , Reincke Martin

The tumorigenesis of Cushing’s disease is characterized by somatic mutations in the USP8 gene in almost half of the cases. USP8 encodes for ubiquitin specific protease 8, a deubiquitinase that rescues proteins involved in the regulation of ACTH synthesis in corticotroph cells. In the present study we tested the antisecretory and antiproliferative efficacy of a commercially available specific USP8 inhibitor (IC50 3.1 μM USP8; >90 μM USP7) in immortalized muri...

ea0056gp198 | Pituitary Basic | ECE2018

Ubiquitin specific peptidase 8 (USP8) in human corticotroph pituitary tumors- possible targets and mode of action

Weigand Isabel , Knobloch Lisanne , Vanselow Jens T , Flitsch Jorg , Monoranu Camelia Maria , Saeger Wolfgang , Hagel Christian , Herterich Sabine , Ronchi Cristina L , Schosser Andreas , Fassnacht Martin , Deutschbein Timo , Sbiera Silviu

Recently, somatic, heterozygous mutations in the gene encoding the deubiquitinase USP8 have been identified in 30–60% of corticotroph tumors. These mutations were found to hinder binding of 14-3-3 proteins, increasing its deubiquitinating activity. One substrate is Epidermal Growth Factor Receptor (EGFR), USP8 triggers EGFR recycling and increased EGFR signaling. However, tumors harboring mutations in USP8 are smaller than WT tumors, raising the debate if EGFR, as a poten...

ea0056gp199 | Pituitary Basic | ECE2018

Prominent expression of MAX and MEG3, despite lack of mutations in MAX, suggest a potential role for 14q genes in pituitary adenomas

Ibanez-Costa Alejandro , Leton Rocio , Rivero-Cortes Esther , Alvarez-Escola Cristina , Poyo-Guerrero Paloma Rodriguez , Gavilan-Villarejo Inmaculada , Korbonits Marta , Marazuela Monica , Galvez-Moreno Maria Angeles , Soto-Moreno Alfonso , Robledo Mercedes , Castano Justo P , Luque Raul M

Pituitary adenomas (PA), as well as pheochromocytomas and paragangliomas, are neuroendocrine tumors that arise from cells derived from the pituitary, adrenal and extra-adrenal nervous system, respectively. Recent studies have identified a growing series of susceptibility genes for these pathologies. Some genes may be associated with the development of both types of pathologies, as it is the case for succinate dehydrogenase complex genes, while, PAs have not been reported to da...

ea0056gp200 | Pituitary Basic | ECE2018

Pharmacological characterization of somatostatin receptor subtype 3 as a potential strategy to treat non-functioning pituitary adenomas

Vazquez-Borrego Mari C , Ibanez-Costa Alejandro , Gahete Manuel D , Toledano-Delgado Alvaro , Blanco-Acevedo Cristobal , Ortega-Salas Rosa , Venegas-Moreno Eva , Vasiljevic Alexandre , Galvez-Moreno Maria A , Soto-Moreno Alfonso , Raverot Gerald , Paez-Pereda Marcelo , Culler Michael D , Castano Justo P , Luque Raul M

Non-functioning pituitary adenomas (NFPAs) represent the most common type of pituitary adenomas. NFPAs are mostly macroadenomas (>1 cm) at diagnosis and, despite their lack of functional hormone hypersecretion, are associated to severe comorbidities related to mass effect (i.e. headaches, visual defects and hypopituitarism). Transsphenoidal surgery is the mainstay of NFPAs treatment, although it is often not definitive, mainly due to the invasion of neighboring intracrania...

ea0056gp201 | Pituitary Basic | ECE2018

Epigenetic and post-transcriptional regulation of the SSTR5 gene in somatotropinomas

Pedraza-Arevalo Sergio , Ibanez-Costa Alejandro , Vazquez-Borrego M Carmen , Branco Miguel , Galvez-Moreno M Angeles , Soto-Moreo Alfonso , Korbonits Marta , Gahete Manuel D , Charalambous Marika , Luque Raul M , Castano Justo P

The somatostatin receptor 5 (sst5) and its truncated splicing variants (sst5TMD5, sst5TMD4) are considered putative biomarkers that can predict pharmacological response or aggressiveness in several endocrine-related pathologies, such as acromegaly. sst5 is encoded by a gene, SSTR5, that lacks introns within its coding sequence, and hence, the splicing variants identified are generated by non-canonical splicing events. However, the mechanisms underlying their genesis a...